AG真人官方

Intellia Therapeutics, Inc. (NTLA) 鈥� Form 4 insider transaction

EVP & Chief Technical Officer Eliana Clark reported the sale of 1,022 common shares on 01 July 2025 at a price of $9.82 per share (transaction code 鈥淪鈥�). The shares had been purchased a day earlier under the company鈥檚 2016 Employee Stock Purchase Plan and were therefore treated as non-derivative shares in Table I.

Following the disposition, Clark鈥檚 direct beneficial ownership stands at 95,369 shares. No derivative securities transactions were reported in Table II, and no Rule 10b5-1 trading plan box was checked, indicating the sale was executed outside of a pre-arranged trading program.

The filing represents a 1.1 % reduction in Clark鈥檚 directly held position (1,022 / 96,391 pre-sale) and is relatively small in dollar terms (~$10,000). No other insiders are included in this filing, and there is no indication of broader strategic implications for NTLA. Investors typically monitor insider activity for sentiment signals; however, a sale of this size by one executive is generally viewed as routine portfolio management rather than a material change in outlook.

Intellia Therapeutics (NTLA) has filed a Form 4 reporting that Vice President & Chief Accounting Officer Michael P. Dube sold 2,503 shares of common stock on 07/02/2025 at $9.95 per share. The filing states this was a mandatory sell-to-cover transaction to satisfy tax-withholding obligations arising from the vesting of restricted stock units (RSUs) on 07/01/2025, rather than a discretionary sale. After the transaction, Dube continues to hold 57,137 shares directly. No derivative positions were reported.

The dollar value of the sale (鈮� $25 k) is immaterial relative to Intellia鈥檚 market capitalization and daily trading volume, and the officer retains a meaningful equity stake. As such, investors are likely to view the disclosure as routine housekeeping with neutral implications for the stock鈥檚 fundamental outlook.

Form 4 filing overview: On 07/02/2025, Chief Executive Officer Michael Heltzen reported an open-market purchase (transaction code 鈥淧鈥�) of 1,040 shares of Exozymes Inc. (ticker EXOZ) common stock at a price of $10.22 per share. Following the transaction, Heltzen鈥檚 direct beneficial ownership increased to 10,628.8 shares. No derivative securities transactions were reported, and the filing was submitted individually (not jointly).

The purchase represents a modest addition to the CEO鈥檚 holdings and is the earliest reportable transaction for the period. Because the form lists no sales or derivative exercises, it signals a net increase in insider ownership.

Intellia Therapeutics, Inc. (NTLA) Form 4: Director Georgia Keresty reported new equity compensation dated 06/11/2025.

• 8,000 restricted stock units (RSUs) granted at $0 cost; each RSU converts into one common share.
• 11,450 stock options with a $8.37 exercise price; the option vests in full on the earlier of the first anniversary of grant or the next annual shareholder meeting and expires 06/10/2035.
• After the grant, Keresty directly owns 31,883 common shares.

No shares were sold or disposed of, and the filing reflects routine non-employee director compensation with negligible dilution and no impact on control or earnings.